Drug Profile
ABBV 257
Alternative Names: ABBV-257; Dual-variable domain immunoglobulins 1; DVD 1; DVD-Ig 1Latest Information Update: 03 Sep 2019
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Class Antirheumatics; Immunoglobulins; Recombinant fusion proteins
- Mechanism of Action Interleukin-17 inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 03 Sep 2019 Discontinued - Phase-I for Rheumatoid arthritis (Treatment-experienced) in Germany (SC)
- 28 Aug 2018 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(Treatment-experienced) in Germany (SC, Injection)
- 01 Feb 2016 AbbVie completes a phase I trial in Rheumatoid arthritis (Treatment-experienced) in Germany (SC) (NCT02531178)